Premium
Multimodality treatment of noninflammatory stage IIIb breast cancer
Author(s) -
Gliński Bogdan,
Pawlicki Marek,
Reinfuss Marian,
Skolyszewski Jan,
Brandys Anna,
Krzemieniecki Krzysztof,
Zuchowska Beata,
Mitus Jerzy,
Stelmach Andrzej,
Walasek Tomasz
Publication year - 1997
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/(sici)1096-9098(199711)66:3<179::aid-jso5>3.0.co;2-9
Subject(s) - medicine , breast cancer , regimen , chemotherapy , radiation therapy , neoadjuvant therapy , cyclophosphamide , mastectomy , oncology , surgery , adjuvant therapy , radical mastectomy , cancer
Background and Objectives The 1990s have established the contribution of multimodality therapy in the management of IIIb noninflammatory breast cancer (IIIb NIBC), by reducing the odds of recurrence and death. Methods A total of 300 women with IIIb NIBC received a multimodality therapy. The treatment consisted of neoadjuvant chemotherapy [FAC (5‐fluorouracil, Adriamycin, cyclophosphamide) regimen], radical (Halsted) mastectomy or modified (Patey mastectomy), postoperative radiotherapy, and adjuvant chemohormone therapy [FAC regimen + cyclophosphamide, 5‐fluorouracil and methotrexate (CMF) regimen or Tamoxifen]. Results Complete or partial clinical response (CR or PR) after neoadjuvant chemotherapy was obtained in 83% patients. Ninety‐nine patients (33%) survived 5 years without evidence of disease (NED). The uni‐ and multivariate analyses factors that had significant influence on the treatment results were: clinical response to neoadjuvant chemotherapy, pathological tumor size, and microscopical status of the axillary lymph nodes. Conclusions We conclude that neoadjuvant FAC regimen chemotherapy is very effective in producing objective tumor regression and offers the benefit of radical mastectomy to patients with previously unresectable IIIb NIBC. J. Surg. Oncol. 1997;66:179–185. © 1997 Wiley‐Liss, Inc.